March 30, 2026 - 17:13

Financial markets experienced a sharp divide in Tuesday's trading session, reflecting investor unease as ongoing conflict in the Middle East fuels uncertainty. The Dow Jones Industrial Average managed to secure gains, while the S&P 500 and Nasdaq Composite both closed lower, dragged down by a significant sell-off in semiconductor stocks.
The tech-heavy Nasdaq felt particular pressure as major chipmakers retreated, signaling a pullback from the previously high-flying artificial intelligence sector. This sector rotation highlighted a cautious move away from growth-oriented investments.
Adding to the market's turbulent mood, the price of U.S. benchmark West Texas Intermediate crude oil surged above $100 per barrel. This jump is directly tied to the escalating conflict, now in its second month, raising concerns about potential supply disruptions and broader inflationary pressures. The combination of erratic political commentary and sustained geopolitical instability is creating a fraught environment for investors, who are balancing strong economic data against the risk of a wider regional war. The day's split performance underscores the market's struggle to find a clear direction amidst competing crosscurrents.
March 30, 2026 - 00:03
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth PlansBiotechnology company Halozyme Therapeutics has announced a key leadership transition, appointing David Ramsay as its interim Chief Financial Officer. The move comes as the firm continues to...
March 29, 2026 - 09:37
SpaceX And Anthropic IPO Frenzy Begins Early As REX Shares, Tuttle Capital File For 2x Leveraged ETFsA race to capitalize on the anticipated public offerings of two tech giants has officially begun, with investment managers filing for specialized funds well before the companies even set a listing...
March 28, 2026 - 20:26
Adobe’s (ADBE) Selloff Isn’t a Buy-the-Dip Opportunity YetAdobe`s stock has experienced a significant downturn, plummeting over 60% from its 2021 high. This dramatic sell-off represents one of the steepest declines the company has faced in recent years....
March 28, 2026 - 04:19
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsCalidi Biotherapeutics has announced significant strides across its clinical pipeline and operational strategy, highlighted by a new partnership and key regulatory feedback. The company has entered...